Top Markets
#1 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.57%
#2 Movement Movement +8.01%
#3 COTI COTI +7.56%
#4 DMT-NAT DMT-NAT +7.27%
#5 Victoria VR Victoria VR +7.18%
#6 GRVT Token GRVT Token +4.67%
#7 Cryptopia Cryptopia +3.74%
#8 Kinetiq Kinetiq +3.53%
#9 Lisk Lisk +3.28%
#10 Jito Jito +3.02%
Coin of the day
FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock)
Settings
Language
ENGLISH
Currency
USD
Theme
AVAX Technologies, Inc. AVAX Technologies, Inc.

AVAX Technologies, Inc.

AVXT
Rank in Stocks #41955
AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on... AVAX Technologies, Inc. is an emerging biopharmaceutical company focused on pioneering autologous cell vaccine methods for cancer therapy. Its pipeline includes lead candidates M-VAX, for melanoma, and O-VAX, targeting ovarian cancer, both of which have successfully concluded Phase II clinical trials. The firm is also developing LungVax, a potential treatment for non-small cell lung cancer. Established in 1990, the Philadelphia, Pennsylvania-based entity initially operated as Walden Laboratories, Inc. before adopting its current name, AVAX Technologies, Inc., in March 1996.
Share Price
$0.00001
Last synced: 2025-12-30
Market Cap
$6.89K
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
US
Trade AVAX Technologies, Inc. (AVXT)

Category

Healthcare
P/E ratio for AVAX Technologies, Inc. (AVXT)
P/E ratio as of 2026 TTM: 0
According to AVAX Technologies, Inc. latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for AVAX Technologies, Inc. from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 28.05 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 31.14 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 19.30 -
BE
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.